Evidence map›Paper›PMID 24076550›Full record

ArticleBone marrow transplantation2014

18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.

C Bodet-Milin, M Lacombe, F Malard, E Lestang, X Cahu, P Chevallier, T Guillaume, J Delaunay, E Brissot, P Moreau and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Radiology. Imaging cancer · 2025
    Trial
  2. Article
  3. Review
  4. Clinical Utility ofJournal of imaging · 2023
    Article
  5. Article
  6. [Bone marrow transplantation · 2022
    Article
  7. Molecular imaging and biology · 2021
    Article
  8. BMC cancer · 2021
    Article
  9. Article
  10. T-Cell Metabolism in GraftFrontiers in immunology · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Applications of PET in Diagnosis and Prognosis of Leukemia.Technology in cancer research & treatment
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

C Bodet-Milin1] Centre Hospitalier et Universitaire (CHU) de Nantes, Service de Médecine Nucléaire Nantes, Nantes, France [2] Université de Nantes, Faculté de Médecine, Nantes, France [3] INSERM CRNCA UMR 892, Nantes, France.
M LacombeICO René Gauducheau, Service de Médecine nucléaire, Saint Herblain/Nantes, France.
F Malard1] INSERM CRNCA UMR 892, Nantes, France [2] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
E LestangCentre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
X CahuCentre Hospitalier et Universitaire (CHU) de Rennes, Service d'Hématologie Clinique, Rennes, France.
P ChevallierCentre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
T GuillaumeCentre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
J DelaunayCentre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
E Brissot1] INSERM CRNCA UMR 892, Nantes, France [2] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
P Moreau1] Université de Nantes, Faculté de Médecine, Nantes, France [2] INSERM CRNCA UMR 892, Nantes, France [3] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France [4] Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France.
F Kraeber-Bodere1] Centre Hospitalier et Universitaire (CHU) de Nantes, Service de Médecine Nucléaire Nantes, Nantes, France [2] Université de Nantes, Faculté de Médecine, Nantes, France [3] INSERM CRNCA UMR 892, Nantes, France [4] ICO René Gauducheau, Service de Médecine nucléaire, Saint Herblain/Nantes, France [5] Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France.
M Mohty1] Université de Nantes, Faculté de Médecine, Nantes, France [2] INSERM CRNCA UMR 892, Nantes, France [3] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France [4] Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France [5] Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, Paris, France [6] Université Pierre et Marie Curie, Paris, France [7] INSERM, UMRs 938, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This prospective pilot study aimed to evaluate the predictive value of (18)F-FDG PET/CT for early diagnosis of acute gastrointestinal GVHD (GI-GVHD). In all, 42 consecutive patients who received allo-SCT were included. (18)F-FDG PET/CT was systematically performed at a median of 28 (range, 24-38) days after allo-SCT. (18)F-FDG PET/CT data review was positive in 15 cases (36%) (9 true positive (TP) cases and 6 false positive (FP) cases) and negative in 27 cases (64%; 26 true negative (TN) cases and 1 false negative (FN) case) at visual analysis. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of (18)F-FDG PET/CT for the diagnosis of acute GI-GVHD were, respectively, 81%, 90%, 60%, 96% and 83%. There were no significant differences of SUVmax values between grade 1-2 GI-GVHD and severe grade 3-4 GI-GVHD. Overall, these preliminary findings suggested that the inflammatory activity of the gastrointestinal tract associated with acute GI-GVHD could be assessed by (18)F-FDG PET/CT suggesting that noninvasive (18)F-FDG PET/CT could become a valuable examination to be performed shortly before endoscopy to map acute GI-GVHD lesions, guide the biopsy sites and choose the appropriate endoscopic procedure, especially in those asymptomatic patients with a positive (18)F-FDG PET/CT.

Indexed as

Fluorodeoxyglucose F18AdultAgedFalse Negative ReactionsFalse Positive ReactionsFemaleGastrointestinal DiseasesGraft vs Host DiseaseHematologic DiseasesHumansMaleMiddle AgedMultimodal ImagingPilot ProjectsPositron-Emission TomographyProspective StudiesFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID24076550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.